Delivery Order SPE2DB20D2014-SPE2DB24FC70G

Award Date 8/8/24
Potential Completion Date 8/9/24
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The contract has a ceiling value of $9,227.86 and a performance period ending on August 8, 2024. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $4,065.21 and runs through January 23, 2025. It is a firm fixed-price contract. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for providing a comprehensive range of pharmaceutical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 30 mg capsules. The total ceiling value of the contract is $1,348.00, with a final completion date of September 22, 2023. The contract is a firm fixed-price delivery order without any set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 40 mg Vyvanse capsules. The contract has a ceiling value of $1,292.02 and an ultimate completion date of September 11, 2024. This award is not associated with a set-aside program. AmerisourceBergen will be supplying the Vyvanse medication, a prescription drug used to treat ADHD, to support various military treatment facilities and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 30 mg capsules. The contract is a firm fixed-price delivery order with a ceiling value of $9,680.28 and an ultimate completion date of August 28, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which serves as a primary...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $2,112.36 and is for the delivery of Vyvanse 20 mg capsules. The contract is a Firm Fixed Price delivery order contract with an ultimate completion date of June 5, 2024. The contract was not set aside for any specific business category. Amerisourcebergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse (lisdexamfetamine dimesylate) 50 mg capsules. The contract has a ceiling value of $2,851.42 and a completion date of August 27, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the DLA to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Vyvanse 20 mg capsules. The order has a ceiling value of $14,202.77 and a completion date of September 11, 2024. The contract is a firm-fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $4,405.36 and a completion date of October 15, 2024. It is a firm fixed-price contract, with no set-aside designation. Amerisourcebergen, through its extensive supply chain network, will provide the DLA with this critical pharmaceutical product to support the healthcare...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,975.52 firm-fixed-price contract is for the delivery of Vyvanse 50 mg capsules. The contract has an ultimate completion date of July 30, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical division, valued at up to $999,999,999 through December 2025, for...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB24FC70G
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Vyvanse 40 mg capsules. The award ceiling is $11,038.94 and the contract has an ultimate completion date of August 9, 2024. This contract is not set aside for a specific business type. AmerisourceBergen holds a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which serves as the primary vehicle for providing pharmaceutical and medical supplies to support military treatment programs and facilities worldwide.

Generated 11/7/24, 9:27 AM